The treatment of rapidly growing mycobacterial infections

Clinics in Chest Medicine

Volumn 36, Issue 1, 2015, Pages 67-78

  Kasperbauer, Shannon H ^a,b   De Groote, Mary Ann ^c  

^a DEPARTMENT OF MEDICINE   (United States)

^b UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^c Department of Environmental and Radiological Health Sciences   (United States)

Author keywords

Antimicrobial resistance; Antimicrobial therapy; Drug susceptibility testing; Mycobacterium abscessus; Mycobacterium massiliense; NTM lung diseases; Surgical therapy

Indexed keywords

AMIKACIN; CEFOXITIN; CIPROFLOXACIN; CLARITHROMYCIN; DOXYCYCLINE; IMIPENEM; MINOCYCLINE; QUINOLONE DERIVATIVE; TIGECYCLINE; TOBRAMYCIN; ANTIINFECTIVE AGENT;

ADVERSE OUTCOME; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ANTIBIOTIC THERAPY; ARTICLE; ATYPICAL MYCOBACTERIOSIS; ATYPICAL MYCOBACTERIUM; BACTERICIDAL ACTIVITY; BACTERIOSTASIS; BACTERIUM ISOLATE; COST OF ILLNESS; DISEASE COURSE; DRUG RESPONSE; EXPERIMENTAL MODEL; GASTROINTESTINAL SYMPTOM; HEALTH CARE COST; HEARING IMPAIRMENT; HIGH THROUGHPUT SEQUENCING; HUMAN; HYPERTRANSAMINASEMIA; LEUKOPENIA; LUNG INFECTION; LUNG RESECTION; MOLECULAR EPIDEMIOLOGY; MYCOBACTERIUM ABSCESSUS; MYCOBACTERIUM ABSCESSUS SUBSP. BOLLETII; NONHUMAN; OUTCOME ASSESSMENT; POSTOPERATIVE INFECTION; RAPIDLY GROWING MYCOBACTERIUM; RASH; SEQUENCE ANALYSIS; SPECIES IDENTIFICATION; SPUTUM CULTURE; SURGICAL INFECTION; THROMBOCYTOPENIA; TINNITUS; TREATMENT DURATION; TREATMENT INDICATION; TREATMENT OUTCOME; VESTIBULAR DISORDER; DRUG EFFECTS; DRUG SCREENING; LUNG DISEASES; MICROBIOLOGY; MYCOBACTERIUM INFECTIONS, NONTUBERCULOUS; PATHOGENICITY;

ANTI-BACTERIAL AGENTS; DRUG EVALUATION, PRECLINICAL; DRUG RESISTANCE, BACTERIAL; HUMANS; LUNG DISEASES; MYCOBACTERIUM INFECTIONS, NONTUBERCULOUS; NONTUBERCULOUS MYCOBACTERIA;

EID: 84922350167     PISSN: 02725231     EISSN: 15578216     Source Type: Journal    
DOI: 10.1016/j.ccm.2014.10.004     Document Type: Review

References (64)

1. Griffith D.E., Aksamit T., Brown-Elliott B.A., et al. An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. Am J Respir Crit Care Med 2007, 175(4):367-416.
2. Griffith D.E., Girard W.M., Wallace R.J. Clinical features of pulmonary disease caused by rapidly growing mycobacteria. An analysis of 154 patients. Am Rev Respir Dis 1993, 147(5):1271-1278.
3. Daley C.L., Griffith D.E. Pulmonary disease caused by rapidly growing mycobacteria. Clin Chest Med 2002, 23(3):623-632. vii.
4. Macheras E., Konjek J., Roux A.L., et al. Multilocus sequence typing scheme for the Mycobacterium abscessus complex. Res Microbiol 2014, 165(2):82-90.
5. Sassi M., Drancourt M. Genome analysis reveals three genomospecies in Mycobacterium abscessus. BMC Genomics 2014, 15:359.
6. Bryant J.M., Grogono D.M., Greaves D., et al. Whole-genome sequencing to identify transmission of Mycobacterium abscessus between patients with cystic fibrosis: a retrospective cohort study. Lancet 2013, 381(9877):1551-1560.
7. Howard S.T. Recent progress towards understanding genetic variation in the Mycobacterium abscessus complex. Tuberculosis 2013, 93(Suppl):S15-S20.
8. Tettelin H., Davidson R.M., Agrawal S., et al. High-level relatedness among Mycobacterium abscessus subsp. massiliense strains from widely separated outbreaks. Emerg Infect Dis 2014, 20(3):364-371.
9. Aitken M.L., Limaye A., Pottinger P., et al. Respiratory outbreak of Mycobacterium abscessus subspecies massiliense in a lung transplant and cystic fibrosis center. Am J Respir Crit Care Med 2012, 185(2):231-232.
10. Bottger E.C. Transmission of M abscessus in patients with cystic fibrosis. Lancet 2013, 382(9891):503-504.
11. Shin S.J., Choi G.E., Cho S.N., et al. Mycobacterial genotypes are associated with clinical manifestation and progression of lung disease caused by Mycobacterium abscessus and Mycobacterium massiliense. Clin Infect Dis 2013, 57(1):32-39.
12. Harada T., Akiyama Y., Kurashima A., et al. Clinical and microbiological differences between Mycobacterium abscessus and Mycobacterium massiliense lung diseases. JClin Microbiol 2012, 50(11):3556-3561.
13. Jeon K., Kwon O.J., Lee N.Y., et al. Antibiotic treatment of Mycobacterium abscessus lung disease: a retrospective analysis of 65 patients. Am J Respir Crit Care Med 2009, 180(9):896-902.
14. Park S., Kim S., Park E.M., et al. Invitro antimicrobial susceptibility of Mycobacterium abscessus in Korea. JKorean Med Sci 2008, 23(1):49-52.
15. Zhuo F.L., Sun Z.G., Li C.Y., et al. Clinical isolates of Mycobacterium abscessus in Guangzhou area most possibly from the environmental infection showed variable susceptibility. Chin Med J 2013, 126(10):1878-1883.
16. Huang Y.C., Liu M.F., Shen G.H., et al. Clinical outcome of Mycobacterium abscessus infection and antimicrobial susceptibility testing. JMicrobiol Immunol Infect 2010, 43(5):401-406.
17. Reddy V.M., O'Sullivan J.F., Gangadharam P.R. Antimycobacterial activities of riminophenazines. JAntimicrob Chemother 1999, 43(5):615-623.
18. Shen G.H., Wu B.D., Hu S.T., et al. High efficacy of clofazimine and its synergistic effect with amikacin against rapidly growing mycobacteria. Int J Antimicrob Agents 2010, 35(4):400-404.
19. van Ingen J., Totten S.E., Helstrom N.K., et al. Invitro synergy between clofazimine and amikacin in treatment of nontuberculous mycobacterial disease. Antimicrob Agents Chemother 2012, 56(12):6324-6327.
20. Wallace R.J., Brown-Elliott B.A., Crist C.J., et al. Comparison of the invitro activity of the glycylcycline tigecycline (formerly GAR-936) with those of tetracycline, minocycline, and doxycycline against isolates of nontuberculous mycobacteria. Antimicrob Agents Chemother 2002, 46(10):3164-3167.
21. Garrison A.P., Morris M.I., Doblecki Lewis S., et al. Mycobacterium abscessus infection in solid organ transplant recipients: report of three cases and review of the literature. Transpl Infect Dis 2009, 11(6):541-548.
22. Peres E., Khaled Y., Krijanovski O.I., et al. Mycobacterium chelonae necrotizing pneumonia after allogeneic hematopoietic stem cell transplant: report of clinical response to treatment with tigecycline. Transpl Infect Dis 2009, 11(1):57-63.
23. Wallace R.J., Dukart G., Brown-Elliott B.A., et al. Clinical experience in 52 patients with tigecycline-containing regimens for salvage treatment of Mycobacterium abscessus and Mycobacterium chelonae infections. JAntimicrob Chemother 2014, 69(7):1945-1953.
24. Greendyke R., Byrd T.F. Differential antibiotic susceptibility of Mycobacterium abscessus variants in biofilms and macrophages compared to that of planktonic bacteria. Antimicrob Agents Chemother 2008, 52(6):2019-2026.
25. Wallace R.J., Meier A., Brown B.A., et al. Genetic basis for clarithromycin resistance among isolates of Mycobacterium chelonae and Mycobacterium abscessus. Antimicrob Agents Chemother 1996, 40(7):1676-1681.
26. Nash K.A., Zhang Y., Brown-Elliott B.A., et al. Molecular basis of intrinsic macrolide resistance in clinical isolates of Mycobacterium fortuitum. JAntimicrob Chemother 2005, 55(2):170-177.
27. Nash K.A., Brown-Elliott B.A., Wallace R.J. Anovel gene, erm(41), confers inducible macrolide resistance to clinical isolates of Mycobacterium abscessus but is absent from Mycobacterium chelonae. Antimicrob Agents Chemother 2009, 53(4):1367-1376.
28. Lee S.H., Yoo H.K., Kim S.H., et al. The drug resistance profile of Mycobacterium abscessus group strains from Korea. Ann Lab Med 2014, 34(1):31-37.
29. Choi G.E., Shin S.J., Won C.J., et al. Macrolide treatment for Mycobacterium abscessus and Mycobacterium massiliense infection and inducible resistance. Am J Respir Crit Care Med 2012, 186(9):917-925.
30. Maurer F.P., Castelberg C., Quiblier C., et al. Erm(41)-dependent inducible resistance to azithromycin and clarithromycin in clinical isolates of Mycobacterium abscessus. JAntimicrob Chemother 2014, 69(6):1559-1563.
31. Jarand J., Levin A., Zhang L., et al. Clinical and microbiologic outcomes in patients receiving treatment for Mycobacterium abscessus pulmonary disease. Clin Infect Dis 2011, 52(5):565-571.
32. Broda A., Jebbari H., Beaton K., et al. Comparative drug resistance of Mycobacterium abscessus and M. chelonae isolates from patients with and without cystic fibrosis in the United Kingdom. JClin Microbiol 2013, 51(1):217-223.
33. Swenson J.M., Wallace R.J., Silcox V.A., et al. Antimicrobial susceptibility of five subgroups of Mycobacterium fortuitum and Mycobacterium chelonae. Antimicrob Agents Chemother 1985, 28(6):807-811.
34. Brown B.A., Wallace R.J., Onyi G.O., et al. Activities of four macrolides, including clarithromycin, against Mycobacterium fortuitum, Mycobacterium chelonae, and M. chelonae-like organisms. Antimicrob Agents Chemother 1992, 36(1):180-184.
35. Wallace R.J., Steele L.C., Forrester G.D., et al. Susceptibilities of Mycobacterium fortuitum biovariant fortuitum and the unnamed third biovariant complex to heavy-metal salts. Antimicrob Agents Chemother 1984, 26(4):594-596.
36. Koh W.J., Jeon K., Lee N.Y., et al. Clinical significance of differentiation of Mycobacterium massiliense from Mycobacterium abscessus. Am J Respir Crit Care Med 2011, 183(3):405-410.
37. Kim H.S., Lee K.S., Koh W.J., et al. Serial CT findings of Mycobacterium massiliense pulmonary disease compared with Mycobacterium abscessus disease after treatment with antibiotic therapy. Radiology 2012, 263(1):260-270.
38. Lyu J., Jang H.J., Song J.W., et al. Outcomes in patients with Mycobacterium abscessus pulmonary disease treated with long-term injectable drugs. Respir Med 2011, 105(5):781-787.
39. Leber A., Marras T.K. The cost of medical management of pulmonary nontuberculous mycobacterial disease in Ontario, Canada. Eur Respir J 2011, 37(5):1158-1165.
40. Yu J.A., Pomerantz M., Bishop A., et al. Lady Windermere revisited: treatment with thoracoscopic lobectomy/segmentectomy for right middle lobe and lingular bronchiectasis associated with non-tuberculous mycobacterial disease. Eur J Cardiothorac Surg 2011, 40(3):671-675.
41. Sugino K., Kobayashi M., Iwata M., et al. Successful treatment with pneumonectomy for pulmonary Mycobacterium abscessus infection. Intern Med 2009, 48(6):459-463.
42. Koh W.J., Kim Y.H., Kwon O.J., et al. Surgical treatment of pulmonary diseases due to nontuberculous mycobacteria. JKorean Med Sci 2008, 23(3):397-401.
43. Duarte R.S., Lourenco M.C., Fonseca Lde S., et al. Epidemic of postsurgical infections caused by Mycobacterium massiliense. JClin Microbiol 2009, 47(7):2149-2155.
44. Furuya E.Y., Paez A., Srinivasan A., et al. Outbreak of Mycobacterium abscessus wound infections among "ipotourists" from the United States who underwent abdominoplasty in the Dominican Republic. Clin Infect Dis 2008, 46(8):1181-1188.
45. Tiwari T.S., Ray B., Jost K.C., et al. Forty years of disinfectant failure: outbreak of postinjection Mycobacterium abscessus infection caused by contamination of benzalkonium chloride. Clin Infect Dis 2003, 36(8):954-962.
46. Munayco C.V., Grijalva C.G., Culqui D.R., et al. Outbreak of persistent cutaneous abscesses due to Mycobacterium chelonae after mesotherapy sessions, Lima, Peru. Rev Saude Publica 2008, 42(1):146-149.
47. Kennedy B.S., Bedard B., Younge M., et al. Outbreak of Mycobacterium chelonae infection associated with tattoo ink. NEngl J Med 2012, 367(11):1020-1024.
48. Song J.Y., Sohn J.W., Jeong H.W., et al. An outbreak of post-acupuncture cutaneous infection due to Mycobacterium abscessus. BMC Infect Dis 2006, 6:6.
49. Sniezek P.J., Graham B.S., Busch H.B., et al. Rapidly growing mycobacterial infections after pedicures. Arch Dermatol 2003, 139(5):629-634.
50. Winthrop K.L., Albridge K., South D., et al. The clinical management and outcome of nail salon-acquired Mycobacterium fortuitum skin infection. Clin Infect Dis 2004, 38(1):38-44.
51. Tsao S.M., Liu K.S., Liao H.H., et al. The clinical management of cesarean section-acquired Mycobacterium abscessus surgical site infections. JInfect Dev Ctries 2014, 8(2):184-192.
52. Ballarino G.J., Olivier K.N., Claypool R.J., et al. Pulmonary nontuberculous mycobacterial infections: antibiotic treatment and associated costs. Respir Med 2009, 103(10):1448-1455.
53. Schackman B.R., Gebo K.A., Walensky R.P., et al. The lifetime cost of current human immunodeficiency virus care in the United States. Med Care 2006, 44(11):990-997.
54. Hutchinson A.B., Farnham P.G., Dean H.D., et al. The economic burden of HIV in the United States in the era of highly active antiretroviral therapy: evidence of continuing racial and ethnic differences. JAcquir Immune Defic Syndr 2006, 43(4):451-457.
55. Maurer F.P., Bruderer V.L., Ritter C., et al. Lack of antimicrobial bactericidal activity in Mycobacterium abscessus. Antimicrob Agents Chemother 2014, 58(7):3828-3836.
56. Lounis N., Gevers T., Van den Berg J., et al. ATP synthase inhibition of Mycobacterium avium is not bactericidal. Antimicrob Agents Chemother 2009, 53(11):4927-4929.
57. Lerat I., Cambau E., Roth Dit Bettoni R., et al. Invivo evaluation of antibiotic activity against Mycobacterium abscessus. JInfect Dis 2014, 209(6):905-912.
58. Howard S.T., Rhoades E., Recht J., et al. Spontaneous reversion of Mycobacterium abscessus from a smooth to a rough morphotype is associated with reduced expression of glycopeptidolipid and reacquisition of an invasive phenotype. Microbiology 2006, 152(Pt 6):1581-1590.
59. Orme I.M., Ordway D.J. The host response to non-tuberculous mycobacterial infections of current clinical importance. Infect Immun 2014, 82:3516-3522.
60. Ordway D., Henao-Tamayo M., Smith E., et al. Animal model of Mycobacterium abscessus lung infection. JLeukoc Biol 2008, 83(6):1502-1511.
61. Oh C.T., Moon C., Park O.K., et al. Novel drug combination for Mycobacterium abscessus disease therapy identified in a Drosophila infection model. JAntimicrob Chemother 2014, 69(6):1599-1607.
62. De Groote M.A., Johnson L., Podell B., et al. GM-CSF knockout mice for preclinical testing of agents with antimicrobial activity against Mycobacterium abscessus. JAntimicrob Chemother 2014, 69(4):1057-1064.
63. Franzblau S.G., DeGroote M.A., Cho S.H., et al. Comprehensive analysis of methods used for the evaluation of compounds against Mycobacterium tuberculosis. Tuberculosis 2012, 92(6):453-488.
64. Olivier KN, Gupta R, Daley CL, etal. A randomized, double-blind, placebo-controlled study of liposomal amikacin for inhalation (Arikace) in patients with recalcitrant nontuberculous mycobacterial lung disease [Publication Number: A4126]. Presented to the American Thoracic Society. San Diego, May 2014.